Log in

Relevant bibliographies by topics / Clinical cancer trials / Dissertations / Theses

To see the other types of publications on this topic, follow the link: Clinical cancer trials.

Dissertations / Theses on the topic 'Clinical cancer trials'

Author: Grafiati

Published: 4 June 2025

Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 dissertations / theses for your research on the topic 'Clinical cancer trials.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.

1

Zhao, Yufan Kosorok Michael R. "Reinforcement learning design for cancer clinical trials." Chapel Hill, N.C. : University of North Carolina at Chapel Hill, 2009. http://dc.lib.unc.edu/u?/etd,2857.

Full text

Abstract:

Thesis (Ph. D.)--University of North Carolina at Chapel Hill, 2009.<br>Title from electronic title page (viewed Jun. 4, 2010). "... in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Biostatistics, School of Public Health." Discipline: Biostatistics; Department/School: Public Health.

APA, Harvard, Vancouver, ISO, and other styles

2

Millar, Joanne Ruth. "Early clinical trials in upper gastrointestinal cancer." Thesis, Queen's University Belfast, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.492011.

Full text

Abstract:

On a worldwide basis, gastric and oesophageal cancer are the third and seventh most common causes of cancer respectively. The majority of patients either present with locally advanced I inoperable or metastatic disease, or develop recurrent disease after potentially curative management. Palliative chemotherapy is therefore a consideration for the majority of patients. Standard chemotherapy in this setting using cisplatin and fluorouracil based regimens does improve survival. However, to date, no randomised trial has shown survival beyond 12 months. There has therefore been considerable early t

APA, Harvard, Vancouver, ISO, and other styles

3

BEDON, LUCA. "Implement Machine Learning Approaches in Cancer Clinical Trials." Doctoral thesis, Università degli Studi di Trieste, 2023. https://hdl.handle.net/11368/3040841.

Full text

Abstract:

Despite improvements, there are still two main reasons why clinical trials fail. These are drug ineffectiveness and drug-induced toxicity, which are primarily the result of poor cohort selection and patient monitoring. Machine learningis an area of artificial intelligence that allows computers to learn without being explicitly programmed by analysing and drawing conclusions from data patterns. This thesis investigated innovative strategies for modernising the process of drug clinical development by incorporating machine learning-based algorithms to uncover clinically significant patterns fro

APA, Harvard, Vancouver, ISO, and other styles

4

Godskesen, Tove. "Patients in Clinical Cancer Trials : Understanding, Motivation and Hope." Doctoral thesis, Uppsala universitet, Centrum för forsknings- och bioetik, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-252542.

Full text

Abstract:

The overall aim of this thesis was to study participants' understanding of clinical cancer trials, and their motivation for participation. Of particular interest was the question of whether the patients hoped for a cure resulting from the trial. The thesis was based on four studies and used three methods: interviews, a questionnaire, and empirical bioethics. The results of Study I indicated that the participants in phase 1 trials understood most of the information provided, but were unaware of both the very small potential for treatment benefit, and the risk of harm. Patients in phase 3 trials

APA, Harvard, Vancouver, ISO, and other styles

5

Sjoquist, Katrin. "Improved decision making from clinical trial evidence in an era of personalised oncology." Thesis, The University of Sydney, 2021. https://hdl.handle.net/2123/27155.

Full text

Abstract:

The program of research reported in this thesis addresses challenges in clinical trial design arising in the era of personalised oncology. Specifically: the value of progression free survival (PFS) as a surrogate for overall survival (OS) in first line trials of advanced ovarian cancer (Ch 2); the use of a control group and subgroup analyses in a randomised phase 2 trial of regorafenib in advanced oesophago-gastric cancer (Ch 3); the value of central review of imaging when used as key end point (Ch 4); and, the ability of a nomogram to improve prognostication in advanced colorectal cancer tria

APA, Harvard, Vancouver, ISO, and other styles

6

Campbell, Ian. "Statistical analysis of end-points in cancer clinical trials." Thesis, University of Cambridge, 1994. https://www.repository.cam.ac.uk/handle/1810/240684.

Full text

Abstract:

The major end-points arising from cancer clinical trials are reviewed. These are: tumour response, treatment morbidity, survival with related data, and quality of life. A survey of tumour response data from 81 published clinical trials found the most common statistical test in use to be a Chi squared test of the total response rate, but a total of 21 different statistical methods were used. The various statistical tests available are reviewed, including the Mann-Whitney test and the Chi squared test for trend which make use of all the categories of response and their intrinsic order. The assum

APA, Harvard, Vancouver, ISO, and other styles

7

Relyea, Stephen L. (Stephen Lawrence). "An analytics approach to designing clinical trials for cancer." Thesis, Massachusetts Institute of Technology, 2013. http://hdl.handle.net/1721.1/82727.

Full text

Abstract:

Thesis (S.M. in Operations Research)--Massachusetts Institute of Technology, Sloan School of Management, Operations Research Center, 2013.<br>This electronic version was submitted by the student author. The certified thesis is available in the Institute Archives and Special Collections.<br>Cataloged from student-submitted PDF version of thesis.<br>Includes bibliographical references (pages 67-71).<br>Since chemotherapy began as a treatment for cancer in the 1940s, cancer drug development has become a multi-billion dollar industry. Combination chemotherapy remains the leading treatment for adv

APA, Harvard, Vancouver, ISO, and other styles

8

Kilgore, Meredith L. "Effects of trial design on participation and costs in clinical trials : with an examination of cost analysis methods and data sources /." Santa Monica, Calif. : Pardee RAND Graduate School, 2004. http://www.rand.org/publications/RGSD/RGSD179.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Hutchison, Catherine B. "A randomised controlled trial of an audiovisual patient information intervention in cancer clinical trials." Thesis, University of Stirling, 2008. http://hdl.handle.net/1893/442.

Full text

Abstract:

Introduction and background Recruitment to cancer clinical trials needs to be improved, as does patient understanding about clinical trials, to enable patients to make an informed choice about whether or not to take part. The main reason that clinically eligible patients do not take part in clinical trials is because they refuse; poor understanding of the research has been associated with patient refusal. Audiovisual patient information (AVPI) has been shown to improve knowledge/understanding in various areas of practice but there is limited information about its effect in the cancer clinical

APA, Harvard, Vancouver, ISO, and other styles

10

譚郭雅欣 and Gloria Tam. "Non-small cell lung cancer clinical trials on new medicines." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2008. http://hub.hku.hk/bib/B41711956.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Vovoras, Dimitrios. "Statistical analysis and modeling: cancer, clinical trials, environment and epidemiology." Scholar Commons, 2011. http://scholarcommons.usf.edu/etd/3397.

Full text

Abstract:

The current thesis is structured in four parts. Vector smoothing methods are used to study environmental data, in particular records of extreme precipitation, the models utilized belong to the vector generalized additive class. In the statistical analysis of observational studies the identification and adjustment for prognostic factors is an important component of the analysis; employing flexible statistical methods to identify and characterize the effect of potential prognostic factors in a clinical trial, namely "generalized additive models", presents an alternative to the traditional line

APA, Harvard, Vancouver, ISO, and other styles

12

Davis, Cheryl Jane. "Psychological factors that influence patient participation in cancer clinical trials." Thesis, University of Hull, 2001. http://hydra.hull.ac.uk/resources/hull:5794.

Full text

Abstract:

The accrual of patients to cancer clinical trials has been noted by a number of authors as a significant problem. Research to date has examined a range of patient and physician related factors that may account for the low accrual rate. Patient refusal as a reason for non-participation has been found by previous research to account for a significant proportion of patients who are not entered onto a trial. This project aimed to explore the differences in attitudes and psychological variables between patients who refused a clinical trial and those who consented. A cross sectional, single point, p

APA, Harvard, Vancouver, ISO, and other styles

13

Waters, A. M. "A core outcome set for clinical trials in oropharyngeal cancer." Thesis, University of Liverpool, 2018. http://livrepository.liverpool.ac.uk/3022643/.

Full text

Abstract:

The impact of randomized controlled trials is frequently diminished by disparate outcome reporting, precluding the comparison of results between trials or synthesis of data in meta-analyses. This is particularly problematic in lower incidence conditions such as oropharyngeal squamous cell carcinoma (OPSCC), where the need to synthesise data from competing trials is greater. Minimum outcome reporting standards, known as Core Outcome Sets (COS) have been shown to increase the consistency of outcome reporting between trials of comparable interventions, thus facilitating the comparison or synthesi

APA, Harvard, Vancouver, ISO, and other styles

14

Tam, Gloria. "Non-small cell lung cancer clinical trials on new medicines." Click to view the E-thesis via HKUTO, 2008. http://sunzi.lib.hku.hk/hkuto/record/B41711956.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Cui, Ye. "Advanced Designs of Cancer Phase I and Phase II Clinical Trials." Digital Archive @ GSU, 2013. http://digitalarchive.gsu.edu/math_diss/15.

Full text

Abstract:

The clinical trial is the most import study for the development of successful novel drugs. The aim of this dissertation is to develop innovative statistical methods to overcome the three main obstacles in clinical trials: (1) lengthy trial duration and inaccurate maximum tolerated dose (MTD) in phase I trials; (2) heterogeneity in drug effect when patients are given the same prescription and same dose; and (3) high failure rates of expensive phase III confirmatory trials due to the discrepancy in the endpoints adopted in phase II and III trials. Towards overcoming the first obstacle, we origin

APA, Harvard, Vancouver, ISO, and other styles

16

Beacon, Heather J. "Statistical analysis of self-assessed quality of life in cancer clinical trials." Thesis, London School of Hygiene and Tropical Medicine (University of London), 1996. http://researchonline.lshtm.ac.uk/682265/.

Full text

Abstract:

The assessment of quality of life as a primary outcome in cancer clinical trials is now almost universal. Such data are necessarily longitudinal and multidimensional, and are often severely unbalanced by missing values or early patient death. However, to date, their reporting in the applied literature has generally used simple descriptive summaries that ignore many of these complexities. Not only can these be misleading, but they generally do not allow firm conclusions to be drawn about a major endpoint. The aim of this thesis is to assess the practical application of recent developments in st

APA, Harvard, Vancouver, ISO, and other styles

17

Parker, Shaunta Shanell. "A Geographic Information System (GIS) Analysis of Cancer Clinical Trial Locations in the State of Georgia by Major Cancer Type." Digital Archive @ GSU, 2008. http://digitalarchive.gsu.edu/iph_theses/21.

Full text

Abstract:

Improving cancer care through clinical research is a major public health issue. However, in Georgia, the exact number of cancer clinical trials is unknown, indicating the need for baseline data regarding cancer clinical trial locations and cancer burden. This study provides the first statewide analysis of cancer clinical trial locations using Geographic Information Systems (GIS). This study examines cancer clinical trial locations by county, according to incidence rates, racial patterns and mortality rates of the four major cancer types: breast, colorectal, lung, and prostate. Findings from th

APA, Harvard, Vancouver, ISO, and other styles

18

Bill-Axelson, Anna. "Localized Prostate Cancer : Results From a Randomized Clinical Trial." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5737.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Procter, Marion J. "Influence of missing explanatory variables and longitudinal assessments in breast cancer clinical trials." Thesis, University of Strathclyde, 2016. http://oleg.lib.strath.ac.uk:80/R/?func=dbin-jump-full&object_id=26931.

Full text

Abstract:

Clinical trials in breast cancer assess treatment regimens based on a balance of efficacy and adverse effects. To achieve high-quality evidence for these assessments, it is important to minimise potential sources of bias. Therefore, potential bias in the parameter estimates resulting from missing observations is an important concern. In this thesis, the influence of missing data on explanatory variables in time-dependent Cox model analysis is explored, with application to breast cancer clinical trials. In particular, imputation in the context of time-dependent covariates that may be informativ

APA, Harvard, Vancouver, ISO, and other styles

20

Middlemiss, Thomas Paul. "A qualitative study exploring advanced cancer patients' experiences of symptom control clinical trials." Thesis, University of Edinburgh, 2012. http://hdl.handle.net/1842/29273.

Full text

Abstract:

Introduction: It has been suggested that conducting clinical trials in palliative care is unethical and may be burdensome for patients. Despite these suggestions, there is evidence that the opinions of patients with advanced cancer are favourable towards clinical trials. However this evidence is based on hypothetical studies; no studies have been done which explore the opinions or experiences of patients who have actually participated in symptom control trials. This thesis is the first study to examine the experiences of advanced cancer patients who have participated in symptom control trials.

APA, Harvard, Vancouver, ISO, and other styles

21

Jackson, Richard. "Some statistical methods for the analysis of survival data in cancer clinical trials." Thesis, University of Liverpool, 2015. http://livrepository.liverpool.ac.uk/2020619/.

Full text

Abstract:

Randomised Clinical Trials (RCT) are one of the most powerful tools of medical re- search and provide the basis for changing clinical practice. In oncology, the RCT is of particular importance in searching for new therapies and treatment approaches for patients diagnosed with cancer. Many of these trials have overall survival as a primary endpoint and are often designed with marginal e�ects being of clinical interest. As a result trials are typically large and are expensive in both time and money. Given the substantial cost involved in running clinical trials, it is an ethical imper- ative tha

APA, Harvard, Vancouver, ISO, and other styles

22

Tate, Wendy Rose. "Evaluation of Efficiency in the Activation and Accrual of Interventional Clinical Trials at Cancer Centers." Diss., The University of Arizona, 2016. http://hdl.handle.net/10150/612064.

Full text

Abstract:

Background: Clinical trials represent a significant percentage of the time and cost to bring a drug through the development process and to Food and Drug Administration approval. Despite how critical these trials are to the drug development process, many studies are underpowered due to low accrual. This translates to valuable questions regarding the safety and effectiveness of new agents being left unanswered, requiring additional time and studies. A call for reform of the industry has been made by stakeholders in the clinical research enterprise; however, national change is slow. Thus site

APA, Harvard, Vancouver, ISO, and other styles

23

Chua, Mei-Sze. "Anti-tumour 2-(4-aminophenyl)benzothiazoles : structurally simple but exciting candidates for clinical trials." Thesis, University of Nottingham, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.324051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Habermehl, Christina [Verfasser], and Annette [Akademischer Betreuer] Kopp-Schneider. "Strategies for cancer clinical trials with multiple biomarkers / Christina Habermehl ; Betreuer: Annette Kopp-Schneider." Heidelberg : Universitätsbibliothek Heidelberg, 2018. http://d-nb.info/1177385627/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Shelby, Rebecca Ann. "Understanding the effectiveness of interventions for cancer patients a study of patient characteristics and intervention evaluations /." Columbus, Ohio : Ohio State University, 2006. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1148322580.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Paton, Elizabeth Jane. "Experiences in improving membership engagement and grant success for clinical research networks in particular for the Australian melanoma and skin cancer community." Thesis, The University of Sydney, 2021. https://hdl.handle.net/2123/27778.

Full text

Abstract:

Introduction The purpose of the thesis is to investigate the important role of clinical trial networks (CTNs), specifically the national cancer cooperative trial groups (CCTGs), have in growing high-quality memberships and optimising grant success to support the undertaking of a greater number of investigator-initiated, high-quality, Australian-led, skin cancer clinical trials. This is critically important in Australia which has the highest skin cancer burden globally. Methodology Experiences from CTNs with a particular focus on the skin CCTG have been evaluated. Two studies have been

APA, Harvard, Vancouver, ISO, and other styles

27

Voskoglou, Theodora. "Clinical predictive value of pre-clinical cancer models, a study of the predictive value of the in vitro cell line, human xenograft and murine allograft pre-clinical cancer models for Phase II clinical trials of cytotoxic cancer drugs." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2001. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/MQ63385.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Maslin-Prothero, Sian. "Factors affecting recruitment to breast cancer clinical trials : an examination of the British Association of Surgical Oncology II trial and the International Breast Cancer Intervention Study." Thesis, University of Nottingham, 2000. http://eprints.nottingham.ac.uk/11954/.

Full text

Abstract:

Breast cancer is the most common form of cancer among women in the United Kingdom, and there is considerable investment in research to identify the causes of breast cancer and the best means of diagnosis and treatments. The randomised controlled trial is the principal method used for evaluating diagnostic and treatment options. Trial organisers depend on recruitment of sufficient numbers of patients in order that the results are statistically significant and generalisable, but accrual to cancer clinical trials is poor. This research analyses factors affecting the accrual of women to two breast

APA, Harvard, Vancouver, ISO, and other styles

29

Grimison, Peter S. "Improving decision-making deriving patient-valued utilities from a disease-specific quality of life questionnaire for evaluating clinical trials /." Connect to full text, 2009. http://hdl.handle.net/2123/5512.

Full text

Abstract:

Thesis (Ph. D.)--University of Sydney, 2009.<br>Title from title screen (viewed Nov. 3, 2009) Includes tables and questionnaires. Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy to the School of Public Health, Faculty of Medicine. Includes bibliography. Also available in print form.

APA, Harvard, Vancouver, ISO, and other styles

30

Camporesi, S. "THE ETHICAL FOUNDATIONS OF CLINICAL RESEARCH: SHIFTING THE PARADIGM OF PARTICIPATION.THE CASE OF PHASE 0 CANCER TRIALS." Doctoral thesis, Università degli Studi di Milano, 2011. http://hdl.handle.net/2434/155519.

Full text

Abstract:

In this dissertation I consider the ethical foundations of clinical research and propose a shift towards a new framework. Since the beginning, the ethical foundations of clinical research have been focused on the protection of human subjects, with a strong emphasis of the importance of the informed consent process and on issues of vulnerability, coercion, and exploitation. This is understandable, as the ethical guidelines regulating clinical research worldwide (Nuremberg Code, Helsinki Declaration, Belmont Report) were born in the aftermath of the WWII. But the historical context has changed,

APA, Harvard, Vancouver, ISO, and other styles

31

Bell, M. L., M. H. Fiero, H. M. Dhillon, V. J. Bray, and J. L. Vardy. "Statistical controversies in cancer research: using standardized effect size graphs to enhance interpretability of cancer-related clinical trials with patient-reported outcomes." Oxford University Press, 2017. http://hdl.handle.net/10150/626025.

Full text

Abstract:

Patient reported outcomes (PROs) are becoming increasingly important in cancer studies, particularly with the emphasis on patient centered outcome research. However, multiple PROs, using different scales, with different directions of favorability are often used within a trial, making interpretation difficult. To enhance interpretability, we propose the use of a standardized effect size graph, which shows all PROs from a study on the same figure, on the same scale. Plotting standardized effects with their 95% confidence intervals (CIs) on a single graph clearly showing the null value conveys a

APA, Harvard, Vancouver, ISO, and other styles

32

Newlands, Rumana. "Design and outcomes of a feasibility randomised controlled trial of lifestyle weight loss intervention in women treated for breast cancer." Thesis, University of Aberdeen, 2016. http://digitool.abdn.ac.uk:80/webclient/DeliveryManager?pid=231668.

Full text

Abstract:

Introduction: Breast cancer is the most frequent cancer among women worldwide. Breast cancer treatments and treatment-related factors (type, dose, duration, and side-effects) have been found to be associated with weight gain in women. Overweight and obesity, in breast cancer survivors, is associated with increased risk of breast cancer-specific and all-cause mortality. Prognosis may be improved by maintaining a healthy weight but research in weight management in women treated for breast cancer is relatively limited. Aim: To design a weight loss trial for women treated for breast cancer and to

APA, Harvard, Vancouver, ISO, and other styles

33

Antunes, de Melo e. Oliveira Ana Mafalda. "Molecular alterations in metastatic breast cancer and efficacy of PI3K/AKT/mTOR inhibitors in early phase clinical trials." Doctoral thesis, Universitat Autònoma de Barcelona, 2017. http://hdl.handle.net/10803/405630.

Full text

Abstract:

Antecedentes: Las alteraciones de la vía de PI3K/AKT/mTOR (PAM) son frecuentes en cáncer de mama metastásico (CMM). Actualmente hay varios inhibidores de PAM en desarrollo. Posibles biomarcadores de respuesta (y resistencia) a estos fármacos y el contexto clínico en el que son más efectivos son poco conocidos. Objetivos: • Principales: (1) Describir las alteraciones moleculares en una cohorte de pacientes con CMM, con especial enfoque en las alteraciones de la vía de PAM. (2) Identificar factores predictivos de respuesta a inhibidores de PAM. • Secundarios: (1) Describir las alteraciones ac

APA, Harvard, Vancouver, ISO, and other styles

34

Koetz, Barbara Susanne. "Evaluation of Positron Emission Tomography to Aid Scheduling of Vascular Targeting and Cytotoxic Cancer Treatments in Clinical Trials." Thesis, University of Manchester, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.508549.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Branford, Ruth Alison. "Clinical trials of cancer-related pain : translational research linking genetic variation to pain experience and response to oral opioids." Thesis, Imperial College London, 2012. http://hdl.handle.net/10044/1/9846.

Full text

Abstract:

Cancer-related pain is a major clinical problem. The World Health Organisation recommends morphine first-line for moderate to severe cancer-related pain, however several other strong opioids are available. There is wide inter-individual variation in morphine response, in terms of analgesic efficacy and side effects. Switching to an alternative opioid such as oxycodone has become common clinical practice to improve outcomes. There has been growing interest in potential genetic factors behind such differences in clinical response. This thesis aimed to compare the overall response rates of morphi

APA, Harvard, Vancouver, ISO, and other styles

36

Goswami, Bhavesh Dineshbhai. "Optimizing Cost and Data Entry for Assignment of Patients to Clinical Trials Using Analytical and Probabilistic Web-Based Agents." [Tampa, Fla.] : University of South Florida, 2003. http://purl.fcla.edu/fcla/etd/SFE0000202.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Andronis, Lazaros. "Analytic approaches for informing research funding decisions : an exploration of their role and value using case studies of cancer clinical trials." Thesis, University of Birmingham, 2013. http://etheses.bham.ac.uk//id/eprint/4153/.

Full text

Abstract:

Patient-level evidence obtained from clinical trials is essential in assessing the cost-effectiveness of health care technologies. Given the increasing demand for primary evidence and limited public resources for health care research, research funding organisations are routinely called to make decisions on which clinical trials to fund. Such decisions need to be informed by evidence on the likely costs and benefits of competing research programmes. Two main analytic approaches have been proposed to provide such evidence, ‘payback of research’ and ‘value of information’. This work applied the ‘

APA, Harvard, Vancouver, ISO, and other styles

38

Cavalli-Björkman, Nina. "Factors Influencing Selection of Treatment for Colorectal Cancer Patients." Doctoral thesis, Uppsala universitet, Enheten för onkologi, 2012. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-172533.

Full text

Abstract:

In Sweden and elsewhere there is evidence of poorer cancer survival for patients of low socioeconomic status (SES), and in some settings differences in treatment by SES have been shown. The aim of this thesis was to explore factors which influence cancer treatment decisions, such as knowledge reaped from clinical trials, patient-related factors, and physician-related factors. In a register study of colorectal cancer, all stages, patients were stratified for SES-factors. Differences were seen with regards to clinical investigation, surgical and oncological treatment and survival, with the highl

APA, Harvard, Vancouver, ISO, and other styles

39

Grimison, Peter. "Improving decision-making: Deriving patient-valued utilities from a disease-specific quality of life questionnaire for evaluating clinical trials." Thesis, The University of Sydney, 2009. http://hdl.handle.net/2123/5512.

Full text

Abstract:

The aim of the work reported in this thesis was to develop a scoring algorithm that converts ratings from a validated disease-specific quality of life questionnaire called the Utility-Based Questionnaire-Cancer (UBQ-C) into a utility index that is designed for evaluating clinical trials to inform clinical decisions about cancer treatments. The UBQ-C includes a scale for global health status (1 item); and subscales for physical function (3 items), social/usual activities (4 items), self-care (1 item), and distresses due to physical and psychological symptoms (21 items). Data from three studies

APA, Harvard, Vancouver, ISO, and other styles

40

Grimison, Peter. "Improving decision-making: Deriving patient-valued utilities from a disease-specific quality of life questionnaire for evaluating clinical trials." Medicine, 2009. http://hdl.handle.net/2123/5512.

Full text

Abstract:

Doctor of Philosophy(PhD)<br>The aim of the work reported in this thesis was to develop a scoring algorithm that converts ratings from a validated disease-specific quality of life questionnaire called the Utility-Based Questionnaire-Cancer (UBQ-C) into a utility index that is designed for evaluating clinical trials to inform clinical decisions about cancer treatments. The UBQ-C includes a scale for global health status (1 item); and subscales for physical function (3 items), social/usual activities (4 items), self-care (1 item), and distresses due to physical and psychological symptoms (21 ite

APA, Harvard, Vancouver, ISO, and other styles

41

Rotolo, Federico. "Frailty multi-state models for the analysis of survival data from multicenter clinical trials." Doctoral thesis, Università degli studi di Padova, 2013. http://hdl.handle.net/11577/3422564.

Full text

Abstract:

Proportional hazards models are among the most popular regression models in survival analysis. Multi-state models generalise them in the sense of jointly considering different types of events along with their interrelations, whereas frailty models introduce random effects to account for unobserved risk factors, possibly shared by groups of subjects. The integration of frailty and multi-state methodology is interesting to control for unobserved heterogeneity in presence of complex event history structures, particularly appealing in multicenter clinical trials applications. In the present thes

APA, Harvard, Vancouver, ISO, and other styles

42

Pradat, Yoann. "Analyses of genomic and transcriptomic proﬁles of metastatic tumors from precision medicine clinical trials". Electronic Thesis or Diss., université Paris-Saclay, 2024. http://www.theses.fr/2024UPASL010.

Full text

Abstract:

À l’ère de l’analyse des données, les connaissances sur l’apparition et la progression du cancer se sont approfondies grâce à l’analyse moléculaire de nombreuses tumeurs dans le monde. Le séquençage de nouvelle génération, apparu dans les années 2000, a transformé la recherche sur les cellules cancéreuses en permettant le profilage complet de l’exome, du transcriptome et même du génome entier. Bien que le séquençage à haut débit ne soit pas systématique dans la pratique clinique, il est couramment utilisé dans les essais thérapeutiques. Le vaste réservoir de données ainsi généré alimente de no

APA, Harvard, Vancouver, ISO, and other styles

43

Hutchings, Elizabeth Helen. "The secondary use and linking of administrative health data and clinical trial data in cancer: attitudes towards data reuse in Australia." Thesis, The University of Sydney, 2021. https://hdl.handle.net/2123/26924.

Full text

Abstract:

Since the introduction of personal computing technology in 1974, the capacity to collect, store, and analyse data has grown exponentially. Terms such as ‘big data’ and ‘data mining’ were coined shortly after with the potential for large datasets and the analysis of stored data to generate important and useful outcomes being recognised early. Since then, the near universal adoption of technology by individuals and organisations has seen data move from being ‘just information’ to an organisational asset which requires clear governance structures and curation. As technology continues to become mo

APA, Harvard, Vancouver, ISO, and other styles

44

Mercieca-Bebber, Rebecca. "Patient-Reported Outcomes in Cancer Clinical Trials: What are the Problems and how can we Improve the Quality and Reporting of Evidence?" Thesis, The University of Sydney, 2017. http://hdl.handle.net/2123/17801.

Full text

Abstract:

Methodological issues may limit the impact and application of patient-reported outcome (PRO) evidence in practice. The broad aims of this thesis were to determine: 1) the nature and effects of methodological problems related to PRO endpoints in cancer clinical trials, and 2) strategies to rectify these problems in future trials to improve the standard of PRO research evidence. Aim 1 was examined by: interviewing trial coordinators about the administration of PRO questionnaires, reviewing published ovarian cancer trials (completeness of PRO content of protocols, missing data rates and completen

APA, Harvard, Vancouver, ISO, and other styles

45

Ebbert, Judith Ann. "Multiple Case Study of Factors Associated with Enrollment of Women with Persistent or Recurrent Ovarian Cancer in Clinical Trials in Central Florida." Scholar Commons, 2016. http://scholarcommons.usf.edu/etd/6230.

Full text

Abstract:

Study Purpose: Ovarian cancer, the most lethal gynecologic cancer, has had a relatively stable mortality rate since 1975, despite a decrease in mortality for all gynecologic cancers combined. Standard-of-care advances are needed to reduce ovarian cancer morbidity and mortality. Advances must, however, undergo a long, rigorously controlled research process that can take more than ten years before becoming available to the public. Further, few women with persistent or recurrent ovarian cancer are offered or enrolled in the clinical trials that do exist at select sites throughout the nation. The

APA, Harvard, Vancouver, ISO, and other styles

46

Conibear, John Richard. "Assessment of target volume and organ at risk contouring variability within the context of UK head and neck and lung cancer radiotherapy clinical trials." Thesis, University College London (University of London), 2018. http://discovery.ucl.ac.uk/10045105/.

Full text

Abstract:

AIMS: Radiotherapy quality assurance (RTQA) is now a requirement of radiotherapy trials since poor target volume and organ at risk (OAR) contouring has been shown to impact on patient outcomes within the context of clinical trials. The first hypothesis for this research is that statistically significant inter-observer variation exists amongst clinical oncologists’ target volume and OAR contours within the context of the pre-trial quality assurance (QA) benchmark cases for four different UK radiotherapy trials. The second hypothesis is directed towards confirming that RTQA feedback during the p

APA, Harvard, Vancouver, ISO, and other styles

47

Stockler, Martin Richard. "Validation of the PROSQOLI as an outcome measure for clinical trials in advanced hormone-resistant prostate cancer, assessment of convergent, discriminative and predictive validity with baseline data from a randomised trial." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1996. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/MQ51552.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Palmer, Daniel Harrison. "A study of the novel VDEPT cancer gene therapy combination nitroreductase / CB1954 : mechanisms of cell death, modulation of cellular signalling pathways and early phase clinical trials." Thesis, University of Birmingham, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.403904.

Full text

Abstract:

A major limitation to the success of cancer gene therapy is the low efficiency of gene delivery achieved by currently available vectors. Virus-directed enzyme prodrug therapy aims to overcome this limitation by delivery of an enzyme to the tumour site, which catalyses the conversion of an inert prodrug to a potent cytotoxic. Activation of the prodrug at the tumour site maximises local cell kill whilst minimising systemic toxicity. Importantly, the activated species should pass to neighbouring nontransduced cells to mediate 'bystander' killing. In this way, significant anti-tumour effects may b

APA, Harvard, Vancouver, ISO, and other styles

49

Shearer, Andrew Jackson. "SELF-REPORTED ADHERENCE TO PHYSICAL ACTIVITY FOR CANCER SURVIVORS: AN UPDATE FROM THE 2015 NHIS DATABASE." UKnowledge, 2017. http://uknowledge.uky.edu/khp_etds/44.

Full text

Abstract:

Cancer is the second leading cause of death in America. It’s been suggested that regular physical activity (PA) can improve health outcomes in cancer survivors. An estimate from BRFSS data (2009) suggested that 47% of all cancer survivors met recommended guidelines and that this estimate was not different from the population at large (48%). Several factors were examined from these BRFSS data to determine whether subgroups of survivors existed who might benefit from interventions aimed at improving their PA status. The purpose of this investigation was to obtain more recent estimates of adheren

APA, Harvard, Vancouver, ISO, and other styles

50

Mombelli, Sarah. "Cancers du sein et immunité anti-tumorale." Thesis, Reims, 2014. http://www.theses.fr/2014REIMS041/document.

Full text

Abstract:

Avec environ 49 000 nouvelles femmes touchées chaque année, le cancer du sein est le plus répandu des cancers féminins. Le dépistage du cancer du sein, ainsi que l'amélioration des traitements ont fait diminuer la mortalité mais il reste encore le plus meurtrier des cancers féminins en France. Le cancer du sein étant une maladie hétérogène, individualiser les traitements des patientes est désormais l'un des objectifs premiers des praticiens. C'est autour de cet objectif commun que se sont articulés les 2 projets de ce travail de thèse. D'une part, pour l'étude clinique, j'ai établi une base de

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!